Expression and clinical significance of SLP-2 in gastric cancer: A meta-analysis

doi:10.3969/j.issn.1004-583X.2022.04.002

Abstract

Abstract:

Objective To evaluate the correlation of the expression and pathology parameters of SLP-2 in gastric cancer.Methods Two researchers independently collected and screened case-control studies regarding SLP-2 expression in gastric cancer in domestic and foreign databases as PubMed, Cochrane Library, EMbase, CBM, CNKI, WanFang Date and VIP databases, the construction time was until November 2021; they assessed the risk of bias for these data and used Revman5.3 software for a meta-analysis.Results Eligible 8 case-control studies were included, with a total of 1079 patients. Meta-analysis showed that the expression level of SLP-2 in gastric cancer tissues was significantly higher than that in adjacent tissues [OR=6.20,95%CI(4.41,8.73),P<0.01]. In gastric cancer tissues, the expression level of SLP-2 in groups with different degrees of differentiation [OR=1.41,95%CI(1.04,1.93),P=0.03], groups with different depth of invasion [OR=3.84,95%CI(2.70,5.47),P<0.01] and groups with different lymph node Metastasis [OR=2.21,95%CI(1.37,3.56),P=0.001], groups with different blood Metastasis [OR=2.05,95%CI(1.25,3.35),P=0.004], groups with different clinical stage [OR=2.79,95%CI(2.08,3.74),P<0.01] was found had statistical significance. Conclusion There are significant difference in SlP-2 expression between gastric cancer tissues and adjacent tissues, which is correlated with clinicopathological parameters, suggesting that SLP-2 plays a role in gastric cancer incidence. Due to the limited quantity and quality of the above literatures, the conclusions should be verified by more high-quality studies.

Key words: stomach neoplasms, stomatin-like protein-2, meta-analysis

CLC Number:

R735.2

Tao Jianan, Tian Wangzhao, An Qi, Wang Xuehong, Zhang Shengqi, Liu Ji. Expression and clinical significance of SLP-2 in gastric cancer: A meta-analysis[J]. Clinical Focus, 2022, 37(4): 299-304.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.04.002

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I4/299

Figures/Tables 7

References 27

[1]	Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492 URL
[2]	王宁, 刘硕, 杨雷, 等. 2018全球癌症统计报告解读[J/CD]. 肿瘤综合治疗电子杂志, 2019, 5(1): 87-97.
[3]	Smyth EC, Nilsson M, Grabsch HI. et al. Gastric cancer[J]. Lancet, 2020, 396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5 URL
[4]	Kiyozumi Y, Iwatsuki M, Yamashita K. et al. Review open access journal of cancer metastasis and treatment update on targeted therapy and immune therapy for gastric cancer, 2018[J]. JCMT, 2021, 4(31):1-15. doi: 10.20517/2394-4722.2017.65 URL
[5]	常栋, 王天佑, 刘芝华. stomatin家族与恶性肿瘤[J/CD]. 中华临床医师杂志(电子版), 2011, 5(2):442-445.
[6]	Guo RL, Wang XR, Wang QG, et al. The regulatory role of SLP-2 and mechanism on CCBE1 gene expression in rectal carcinoma and adjacent lymphatic tube tissues[J]. Eur Rev Med Pharmacol Sci, 2018, 22(1):87-94.
[7]	Zhang J, Song X, Li C. et al. Expression and clinical significance of SLP-2 in ovarian tumors[J]. Oncol Lett, 2019, 17(5):4626-4632.
[8]	Zhou C, Li Y, Wang G. et al. Enhanced SLP-2 promotes invasion and metastasis by regulating Wnt/β-catenin signal pathway in colorectal cancer and predicts poor prognosis[J]. Pathol Res Pract, 2019, 215(1):57-67. doi: 10.1016/j.prp.2018.10.018 URL
[9]	张佳露, 胡国林, 刘磊, 等. 沉默SLP-2可抑制人宫颈癌细胞的迁移及侵袭能力[J]. 南方医科大学学报, 2018, 38(7):812-817.
[10]	Wang WX, Lin QF, Shen D. et al. Clinicopathological significance of SLP-2 overexpression in human gallbladder cancer[J]. Tumour Biol, 2014, 35(1):419-423. doi: 10.1007/s13277-013-1058-7 URL
[11]	Huang Y, Chen Y, Lin X. et al. Clinical significance of SLP-2 in hepatocellular carcinoma tissues and its regulation in cancer cell proliferation, migration, and EMT[J]. Onco Targets Ther, 2017, 20(10):4665-4673.
[12]	Chang D, Ma K, Gong M. et al. SLP-2 overexpression is associated with tumour distant metastasis and poor prognosis in pulmonary squamous cell carcinoma[J]. Biomarkers, 2010, 15(2):104-110. doi: 10.3109/13547500903311910 pmid: 19839737
[13]	Li XH, He F, Yan SM. et al. Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: A retrospective study[J]. Med Oncol, 2014, 31(1):763. doi: 10.1007/s12032-013-0763-9 URL
[14]	Liu D, Zhang L, Shen Z. et al. Increased levels of SLP-2 correlate with poor prognosis in gastric cancer[J]. Gastric Cancer, 2013, 16(4):498-504. doi: 10.1007/s10120-013-0232-3 URL
[15]	Ma W, Xu Z, Wang Y. et al. A positive feedback loop of SLP2 activates MAPK signaling pathway to promote gastric cancer progression[J]. Theranostics, 2018, 8(20):5744-5757. doi: 10.7150/thno.28898 URL
[16]	张剑, 李建生, 吴敏, 等. SLP-2在胃癌组织中的表达及对胃腺癌细胞SGC7901运动侵袭的影响[J]. 中华消化杂志, 2013, 33(1):37-41.
[17]	王东建. 胃癌中EGFR、SLP-2和IGF-1R的表达及其与临床病理特征的关系[J]. 大医生, 2019, 4(22):27-29.
[18]	芦永福, 王学红, 王昀, 等. SLP-2、CDC42在胃上皮内瘤变和胃癌中的表达及意义[J]. 青海医学院学报, 2015, 36(1):34-40.
[19]	颜淑梅, 吴秋良, 奚少彦, 等. SLP-2在胃癌组织中的表达及其预后意义[J]. 中国病理生理杂志, 2012, 28(12):2192-2196.
[20]	饶兰, 马虎. SLP-2和IGF-1R在胃癌组织中的表达及意义[J]. 四川医学, 2014, 35(12):1545-1548.
[21]	Wang Y, Morrow JS. Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues[J]. J Biol Chem, 2000, 275(11):8062-8071. doi: 10.1074/jbc.275.11.8062 pmid: 10713127
[22]	张立勇, 王涛, 丁芳, 等. SLP-2基因在食管鳞癌中的差异表达及其生物信息学分析[J]. 世界华人消化杂志, 2004, 12(7):11-15.
[23]	Yang CT, Li JM, Li LF. et al. Stomatin-like protein 2 regulates survivin expression in non-small cell lung cancer cells through β-catenin signaling pathway[J]. Cell Death Dis, 2018, 9(4):425. doi: 10.1038/s41419-018-0461-9 URL
[24]	Rahmani F, Avan A, Hashemy SI. et al. Role of Wnt/β-catenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer[J]. J Cell Physiol, 2018, 233(2): 811-817. doi: 10.1002/jcp.25897 pmid: 28266708
[25]	Hu G, Zhang J, Xu F. et al. Stomatin-like protein 2 inhibits cisplatin-induced apoptosis through MEK/ERK signaling and the mitochondrial apoptosis pathway in cervical cancer cells[J]. Cancer Sci, 2018, 109(5):1357-1368. doi: 10.1111/cas.13563 URL
[26]	Liu Q, Li A, Wang L. et al. Stomatin-like protein 2 promotes tumor cell survival by activating the JAK2-STAT3-PIM1 pathway, suggesting a novel therapy in colorectal cancer[J]. Mol Ther Oncolytics, 2020, 30(17):169-179.
[27]	Guo XY, Guo HF, Guo HM. Clinical significance of SLP-2 in epithelial ovarian cancer and its regulatory effect on the Notch signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(4):1666-1671.

纳入研究	国家及地区	例数	性别 (男/女,例)	中位年龄 (岁)	试验方法	胃癌SLP-2 阳性率(%)	癌旁SLP-2 阳性率(%)	结局指标
Li 2014^[13]	中国江苏	451	314/137	58(17-85)	IHC	69.8	-	②③④⑤⑥⑦⑧⑨
Liu 2013^[14]	中国广东	113	51/62	63(28-92)	IHC	62.8	23.3	①②③④⑤⑥⑦⑧⑨
Ma 2018^[15]	中国广东	105	70/35	-	IHC	75.2	-	②③⑤⑥⑦⑨
张剑 2013^[16]	中国河南	60	37/23	65(45-79)	IHC	68.3	25.0	①②③④⑤⑥⑦
王东建 2019^[17]	中国江苏	80	44/36	-	IHC	65.0	22.5	①②③⑥⑦
芦永福 2015^[18]	中国青海	30	-	45(34-70)	IHC	56.7	20.0	①
颜淑梅 2012^[19]	中国广东	190	130/60	58(20-82)	IHC	63.2	-	②③④⑤⑥⑦⑧⑨
饶兰 2014^[20]	中国湖北	50	32/18	-	IHC	66.0	20.0	①②③⑤⑥

纳入研究	国家及地区	例数	性别 (男/女,例)	中位年龄 (岁)	试验方法	胃癌SLP-2 阳性率(%)	癌旁SLP-2 阳性率(%)	结局指标
Li 2014^[13]	中国江苏	451	314/137	58(17-85)	IHC	69.8	-	②③④⑤⑥⑦⑧⑨
Liu 2013^[14]	中国广东	113	51/62	63(28-92)	IHC	62.8	23.3	①②③④⑤⑥⑦⑧⑨
Ma 2018^[15]	中国广东	105	70/35	-	IHC	75.2	-	②③⑤⑥⑦⑨
张剑 2013^[16]	中国河南	60	37/23	65(45-79)	IHC	68.3	25.0	①②③④⑤⑥⑦
王东建 2019^[17]	中国江苏	80	44/36	-	IHC	65.0	22.5	①②③⑥⑦
芦永福 2015^[18]	中国青海	30	-	45(34-70)	IHC	56.7	20.0	①
颜淑梅 2012^[19]	中国广东	190	130/60	58(20-82)	IHC	63.2	-	②③④⑤⑥⑦⑧⑨
饶兰 2014^[20]	中国湖北	50	32/18	-	IHC	66.0	20.0	①②③⑤⑥

纳入研究	①	②	③	④	⑤	⑥	⑦	⑧	NOS评分(分)
Li 2014^[13]	1	1	1	1	2	1	1	1	9
Liu 2013^[14]	1	1	1	0	1	1	1	1	7
Ma 2018^[15]	1	1	1	1	1	1	1	1	8
张剑 2013^[16]	1	1	1	1	2	1	1	1	9
王东建 2019^[17]	1	1	1	1	1	1	1	1	8
芦永福 2015^[18]	1	1	1	1	1	1	1	1	8
颜淑梅 2012^[19]	1	1	1	0	2	1	1	1	8
饶兰 2014^[20]	1	1	1	1	2	1	1	1	9

纳入研究	①	②	③	④	⑤	⑥	⑦	⑧	NOS评分(分)
Li 2014^[13]	1	1	1	1	2	1	1	1	9
Liu 2013^[14]	1	1	1	0	1	1	1	1	7
Ma 2018^[15]	1	1	1	1	1	1	1	1	8
张剑 2013^[16]	1	1	1	1	2	1	1	1	9
王东建 2019^[17]	1	1	1	1	1	1	1	1	8
芦永福 2015^[18]	1	1	1	1	1	1	1	1	8
颜淑梅 2012^[19]	1	1	1	0	2	1	1	1	8
饶兰 2014^[20]	1	1	1	1	2	1	1	1	9